Return to Home

Checkpoint Therapeutics, Inc.

CKPT

Find Out if You Qualify for a Financial Reward by filling out the form below.

Checkpoint Therapeutics, Inc. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

On December 18, 2023, Checkpoint issued a press release announcing that the U.S. Food and Drug Administration had issued a complete response letter for the cosibelimab biologic license application for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. According to Checkpoint’s release, “[t]he CRL only cites findings that arose during a multi-sponsor inspection of Checkpoint’s third-party contract manufacturing organization as approvability issues to address in a resubmission.” Checkpoint’s President and Chief Executive Officer stated that “we believe we can address the feedback in a resubmission to enable marketing approval in 2024”.

On this news, Checkpoint’s stock price dropped 44.88%, to close at $1.83 per share on December 18, 2023.

Find More Cases

Ticker Symbol Company Name Join Deadline
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join
PCRX Pacira BioSciences, Inc. March 14, 2025 Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join
GSK GSK plc April 07, 2025 Join
NTLA Intellia Therapeutics, Inc. April 14, 2025 Join
MRK Merck & Co., Inc. April 14, 2025 Join